Illumina | GenomeWeb

Illumina

 

Illumina is a developer, manufacturer, and marketer of life science tools and integrated systems for large-scale analysis of genetic variation and function. Illumina has developed a line of products that address the scale of experimentation and breadth of functional analysis to advance disease research, drug development, and the development of molecular tests.

Illumina Facts

 

CEO: Jay Flatley

Website: www.illumina.com

Ticker symbol: ILMN

Headquarters: San Diego, CA

Number of employees: 3,750+ globally

The companies will work together to seek FDA clearance or approval for a number of biomarker and immuno-oncology assay kits for use on the MiSeqDx.

The activity follows a recent financing round that has enabled OncoDNA to build out its sales team as it courts new clients.

Illumina launched the program in 2014 to provide genomics startups with access to capital, business assistance, and technical expertise.

The GenomeWeb Index rose more than 6 percent in January, outperforming the Dow, Nasdaq, and Nasdaq Biotechnology Index.

Researchers fear the executive order will have long-lasting effects on the US' ability to recruit top talent, and will make the country less attractive as an international conference venue.

Illumina's Q4 revenues were in line with a previous estimate of $619 million and beat analysts' average expectation.

Illumina said the registration for its analysis software is the first step toward launching a full CE-IVD VeriSeq NIPT assay in Europe.

CareDx's CareDx Pty subsidiary said it will pay up to $735,000 to Conexio as a percentage of revenues from products acquired in the deal. 

The bank rated companies like Thermo Fisher Scientific and Agilent at Buy, Illumina and PerkinElmer at Hold, and Myriad Genetics and Luminex at Sell.

Under the terms of the deals, Illumina and Monsanto will have access to NRGene's genome assembly and analysis technologies for ag-bio research projects.

Pages

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.